PharmaBoardroom

Pierre Morneau – General Manager, Takeda Switzerland

Pierrre Morneau of Takeda Switzerland explains the therapeutic areas at the core of the company, equitable access, the Swiss framework for rare…

Charles Chen – Vice Chairman & CEO, Medigen Vaccine…

Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company's COVID-19 vaccine strategy, and what…

Aducanumab edges closer to Potential Approval: Next up, the…

In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory…

Emerging Markets: How COVID-19 is Throwing New Light on the Role…

Dr Ann Aerts, head of the Novartis Foundation, highlights how the COVID-19 crisis has thrust artificial intelligence in healthcare into the limelight,…

Alan Knox – Group CEO, Primex Pharmaceuticals

Alan Knox of Primex Pharmaceuticals explains how the COVID-19 pandemic has thrust the anaesthesia field back into the global spotlight, the benefits…

Four Cell & Gene Companies to Know in China

While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese…

Importing Drugs from Canada: America’s Zombieland Sequel

Market access and pricing expert Barbara Jaszewski outlines the issues inherent in the USA importing drugs from Canada and why such proposals retain…

PhRMA CEO on ‘Tireless’ Industry COVID-19 Response &…

Stephen J. Ubl, president and CEO of PhRMA, outlines the unprecedented collaboration and speed with which the biopharmaceutical industry has responded…